We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.98B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+33.7%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.98B
AUM Growth
+$220M
(+12%)
Cap. Flow
+$217M
Cap. Flow
% of AUM
10.92%
Top 10 Holdings %
Top 10 Hldgs %
59.28%
Holding
52
New
17
Increased
6
Reduced
17
Closed
3
Top Buys
| 1 |
Erasca
ERAS
|
+$68.6M |
| 2 |
Dianthus Therapeutics
DNTH
|
+$55M |
| 3 |
DMRA
Damora Therapeutics
DMRA
|
+$39.2M |
| 4 |
AGMB
AgomAb Therapeutics NV
AGMB
|
+$34.9M |
| 5 |
MAZE
Maze Therapeutics
MAZE
|
+$33.1M |
Top Sells
| 1 |
ABVX
Abivax
ABVX
|
+$69.8M |
| 2 |
enGene Therapeutics
ENGN
|
+$36.1M |
| 3 |
BridgeBio Pharma
BBIO
|
+$25.4M |
| 4 |
Praxis Precision Medicines
PRAX
|
+$20M |
| 5 |
GH Research
GHRS
|
+$16.5M |
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Financials | 0.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ascendis Pharma A/S
ASND
$17.4B
| $21.7M | 1.1% |
95,000
-5,000
| -5% | -$1.12M |
|
27
Roivant Sciences
ROIV
$25.1B
| $20.8M | 1.05% |
+750,000
| New | +$19.3M |
|
|
ANL
28
Adlai Nortye
ANL
$592M
| $20.1M | 1.01% |
+2,897,857
| New | +$19.4M |
|
|
TERN
29
DELISTED
Terns Pharmaceuticals
TERN
| $15.8M | 0.8% |
+300,000
| New | +$12.3M |
|
30
Tarsus Pharmaceuticals
TARS
$2.45B
| $15.8M | 0.8% |
225,000
-25,000
| -10% | -$1.75M |
|
31
Biohaven
BHVN
$2.25B
| $14.9M | 0.75% |
1,760,000
+1,750,000
| +17,500% | +$19.1M |
|
32
Cabaletta Bio
CABA
$435M
| $14.8M | 0.75% |
5,500,000
+1,100,000
| +25% | +$3.05M |
|
|
HLXC
33
Helix Acquisition Corp III
HLXC
$227M
| $13.2M | 0.66% |
+1,297,500
| New | +$13.3M |
|
34
Arcutis Biotherapeutics
ARQT
$3.35B
| $10.6M | 0.53% |
450,000
-50,000
| -10% | -$1.28M |
|
|
FTH
35
Faeth Therapeutics
FTH
$854M
| $9.65M | 0.49% |
+306,222
| New | +$6.12M |
|
36
Crinetics Pharmaceuticals
CRNX
$8.86B
| $9.08M | 0.46% |
250,000
-50,000
| -17% | -$2.23M |
|
37
Zura Bio
ZURA
$481M
| $8.63M | 0.43% |
+1,450,000
| New | +$8.76M |
|
38
Axsome Therapeutics
AXSM
$12.1B
| $8.45M | 0.43% |
50,000
-25,000
| -33% | -$4.32M |
|
39
Structure Therapeutics
GPCR
$3.6B
| $8.44M | 0.43% |
+175,000
| New | +$12M |
|
40
Cogent Biosciences
COGT
$6.58B
| $7.7M | 0.39% |
200,000
-25,000
| -11% | -$923K |
|
41
Monte Rosa Therapeutics
GLUE
$1.98B
| $6.58M | 0.33% |
+400,000
| New | +$7.65M |
|
42
Arrowhead Research
ARWR
$10.1B
| $6.27M | 0.32% |
+100,000
| New | +$6.33M |
|
43
Vaxcyte
PCVX
$8.12B
| $5.81M | 0.29% |
100,000
-25,000
| -20% | -$1.36M |
|
44
Amylyx Pharmaceuticals
AMLX
$2.02B
| $4.87M | 0.25% |
350,000
-50,000
| -13% | -$703K |
|
45
Rallybio
RLYB
$92.9M
| $3.59M | 0.18% |
+400,000
| New | +$2.73M |
|
46
Context Therapeutics
CNTX
$57.2M
| $1.39M | 0.07% |
+529,550
| New | +$1.24M |
|
|
47
enGene Therapeutics
ENGN
$127M
| – | – |
-4,000,000
| Closed | -$36.1M |
|
|
48
GH Research
GHRS
$1.84B
| – | – |
-1,300,000
| Closed | -$16.5M |
|
49
iShares Russell 2000 ETF
IWM
$82.3B
| – | – |
0
| – | – |
|
50
Janux Therapeutics
JANX
$962M
| – | – |
-650,000
| Closed | -$8.97M |
|
Similar funds
RMCM
FWTB
SC
SSWM
SI
TCM
CWM
RCM